Recent advances in molecular targeted therapy of lung cancer: Possible application in translation medicine

Document Type : Review Article

Authors

1 Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Medical Biochemistry, Faculty of Medicine, Istanbul Aydin University, Istanbul, Turkey

Abstract

Lung cancer is one of the leading causes of death among all cancer deaths. This cancer is classified into two different histological subtypes: non-small cell lung cancer (NSCLC), which is the most common subtype, and small cell lung cancer (SCLC), which is the most aggressive subtype. Understanding the molecular characteristics of lung cancer has expanded our knowledge of the cellular origins and molecular pathways affected by each of these subtypes and has contributed to the development of new therapies. Traditional treatments for lung cancer include surgery, chemotherapy, and radiotherapy. Advances in understanding the nature and specificity of lung cancer have led to the development of immunotherapy, which is the newest and most specialized treatment in the treatment of lung cancer. Each of these treatments has advantages and disadvantages and causes side effects. Today, combination therapy for lung cancer reduces side effects and increases the speed of recovery. Despite the significant progress that has been made in the treatment of lung cancer in the last decade, further research into new drugs and combination therapies is needed to extend the clinical benefits and improve outcomes in lung cancer. In this review article, we discussed common lung cancer treatments and their combinations from the most advanced to the newest.

Keywords

Main Subjects

References

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72:7-33.
2. Tokgun O, Karakas DE, Tan S, Karagür ER, İnal B, Akca H, et al. Novel ruthenium and palladium complexes as potential anticancer molecules on SCLC and NSCLC cell lines. Chem Pap 2020; 74:2883-2892.
3. Turner RM, Chen YW, Fernandes AW. Validation of a case-finding algorithm for identifying patients with non-small cell lung cancer (nsclc) in administrative claims databases. Front Pharmacol 2017; 8:883-890.
4. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc 2019; 94:1623-1640.
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553:446-454.
6. Nagasaka M, Gadgeel SM. Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther 2018; 18:63-70.
7. Cai W-Q, Zeng L-S, Wang L-F, Wang Y-Y, Cheng J-T, Zhang Y, et al. The latest battles between EGFR monoclonal antibodies and resistant tumor cells. Front Oncol 2020; 10:1249-1264.
8. Su C, Ren X, Nie F, Li T, Lv W, Li H, et al. Current advances in ultrasound-combined nanobubbles for cancer-targeted therapy: A review of the current status and future perspectives. RSC Adv 2021; 11:12915-12928.
9. Hassani N, Jafari-Gharabaghlou D, Dadashpour M, Zarghami N. The effect of dual bioactive compounds artemisinin and metformin co-loaded in PLGA-PEG nano-particles on breast cancer cell lines: potential apoptotic and anti-proliferative action. Appl Biochem Biotechnol 2022; 194:4930-4945.
10. Xiong R, Xu RX, Huang C, De Smedt S, Braeckmans K. Stimuli-responsive nanobubbles for biomedical applications. Chem Soc Rev 2021; 50:5746-5776.
11. Alagheband Y, Jafari-gharabaghlou D, Imani M, Mousazadeh H, Dadashpour M, Firouzi-Amandi A, et al. Design and fabrication of a dual-drug loaded nano-platform for synergistic anticancer and cytotoxicity effects on the expression of leptin in lung cancer treatment. J Drug Deliv Sci Technol. 2022; 73:103389.
12. Islam KM, Anggondowati T, Deviany PE, Ryan JE, Fetrick A, Bagenda D, et al. Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer. BMC Cancer 2019; 19:835-843.
13. Sihoe AD. Video‐assisted thoracoscopic surgery as the gold standard for lung cancer surgery. Respirol 2020; 25:49-60.
14.Woodman C, Vundu G, George A, Wilson CM, editors. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer. Semin Cancer Biol 2021; 69:349-364.
15. van Dorp M, Beck N, Steup WH, Schreurs WH. Surgical treatment of pulmonary metastases in the Netherlands: Data from the dutch lung cancer audit for surgery. Eur J Cardiothorac Surg 2020; 58:768-774.
16. Casiraghi M, Bertolaccini L, Sedda G, Petrella F, Galetta D, Guarize J, et al. Lung cancer surgery in oligometastatic patients: outcome and survival. Eur J Cardiothorac Surg 2020; 57:1173-1180.
17. Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, et al. Screening for lung cancer: US Preventive Services Task Force recommendation statement. JAMA 2021; 325:962-970.
18. Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol 2017; 8:1-20.
19. Kobayashi N, Kobayashi K, Kikuchi S, Goto Y, Ichimura H, Endo K, et al. Long-term pulmonary function after surgery for lung cancer. Interact Cardiovasc Thorac Surg 2017; 24:727-732.
20. Salazar MC, Rosen JE, Wang Z, Arnold BN, Thomas DC, Herbst RS, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol 2017; 3:610-619.
21. Duan J, Yang Z, Liu D, Shi Y. Clinical efficacy of bevacizumab combined with gemcitabine and cisplatin combination chemotherapy in the treatment of advanced non-small cell lung cancer. J BUON 2018; 23:1402-1406.
22. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med  2002; 346:92-98.
23. Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors. J Thorac Oncol  2021; 16:1086-1098.
24. Xiao Q, Zhu W, Feng W, Lee SS, Leung AW, Shen J, et al. A review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy. Front Pharmacol 2018; 9:1534-1543.
25. Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomed (Taipei) 2017; 7:12-23.
26. Bashir D. Chemotherapy for Cancer: What It Is and How It Works.  2023.
27. Grewal DS. Nanotechnology as an Alternative to Chemotherapy. Int J Nanotechnol Nanomed, 6: 2021; 41-43.
28. Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Drug resistance in non-small cell lung cancer: A potential for NOTCH targeting? Front Oncol 2018; 8:267-289.
29. Jafari-Gharabaghlou D, Dadashpour M, Khanghah OJ, Salmani-Javan E, Zarghami N. Potentiation of folate-functionalized PLGA-PEG nanoparticles loaded with metformin for the treatment of breast Cancer: possible clinical application. Mol Biol Rep 2023; 50:3023-3033.
30. Sooman L, Gullbo J, Bergqvist M, Bergstrom S, Lennartsson J, Ekman S. Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. BMC Res Notes 2017; 10:544-552.
31. Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, et al. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer reports 2022; 5:e1291.
32. Katayama R. Drug resistance in anaplastic lymphoma kinase‐rearranged lung cancer. Cancer Sci 2018; 109:572-580.
33. Davoudi Z, Akbarzadeh A, Rahmatiyamchi M, Movassaghpour AA, Alipour M, Nejati-Koshki K, et al. Molecular target therapy of AKT and NF-kB signaling pathways and multidrug resistance by specific cell penetrating inhibitor peptides in HL-60 cells. Asian Pac J Cancer Prev 2014; 15:4353-4358.
34. Jagodinsky JC, Harari PM, Morris ZS. The promise of combining radiation therapy with immunotherapy. Int J Radiat Oncol Biol Phys 2020; 108:6-16.
35. Mi Y, Shao Z, Vang J, Kaidar-Person O, Wang AZ. Application of nanotechnology to cancer radiotherapy. Cancer Nanotechnol 2016; 7:1-16.
36. Xu J, Gao J, Wei Q. Combination of photodynamic therapy with radiotherapy for cancer treatment. J Nanomater 2016; 2016:1-7.
37. Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 2018; 24:1845-1851.
38. Chen HH, Kuo MT. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget 2017; 8:62742.
39. Baker S, Dahele M, Lagerwaard FJ, Senan S. A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol 2016; 11:115-128.
40. Vinod SK, Hau E. Radiotherapy treatment for lung cancer: Current status and future directions. Respirol 2020; 25 Suppl 2:61-71.
41. Ricardi U, Badellino S, Filippi AR. Stereotactic radiotherapy for early stage non-small cell lung cancer. Radiat Oncol J 2015; 33:57-65.
42. Berman AT, Jabbour SK, Vachani A, Robinson C, Choi JI, Mohindra P, et al. Empiric radiotherapy for lung cancer collaborative group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation. Transl Lung Cancer Res 2019; 8:5-14.
43. Liao Z, Jiang W, Ye L, Li T, Yu X, Liu L. Classification of extrachromosomal circular DNA with a focus on the role of extrachromosomal DNA (ecDNA) in tumor heterogeneity and progression. Biochim Biophys Acta  Rev Cancer 2020; 1874:188392.
44. D’Andrea MA, Reddy GK. Systemic antitumor effects and abscopal responses in melanoma patients receiving radiation therapy. Oncology 2020; 98:202-215.
45. Agrawal V, Benjamin KT, Ko EC. Radiotherapy and immunotherapy combinations for lung cancer. Curr Oncol Rep 2021; 23:1-9.
46. Wirsdorfer F, de Leve S, Jendrossek V. Combining radiotherapy and immunotherapy in lung cancer: Can we expect limitations due to altered normal tissue toxicity? Int J Mol Sci 2018; 1-21.
47. Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity 2020; 52:17-35.
48. Hayes C. Cellular immunotherapies for cancer. Ir J Med Sci 2021; 190:41-57.
49. Villanueva N, Bazhenova L. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. Ther Adv Respir Dis 2018; 12:1753466618794133.
50. Li L, Jiang M, Qi L, Wu Y, Song D, Gan J, et al. Pyroptosis, a new bridge to tumor immunity. Cancer Sci 2021; 112:3979-3994.
51. Cella E, Zullo L, Marconi S, Rossi G, Coco S, Dellepiane C, et al. Immunotherapy-chemotherapy combinations for non-small cell lung cancer: Current trends and future perspectives. Expert Opin Biol Ther 2022; 22:1259-1273.
52. Schuster M, Nechansky A, Kircheis R. Cancer immunotherapy. Biotechnol J 2006; 1:138-147.
53. Jain P, Jain C, Velcheti V. Role of immune-checkpoint inhibitors in lung cancer. Ther Adv Respir Dis 2018; 12:1753465817750075.
54. Zhang H, Chen J. Current status and future directions of cancer immunotherapy. J Cancer 2018; 9:1773-1781.
55. Anagnostou VK, Brahmer JR. Cancer immunotherapy: A future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res 2015; 21:976-984.
56. Kuol N, Stojanovska L, Nurgali K, Apostolopoulos V. The mechanisms tumor cells utilize to evade the host’s immune system. Maturitas 2017; 105:8-15.
57. Creelan BC. Update on immune checkpoint inhibitors in lung cancer. Cancer Control 2014; 21:80-89.
58. Farran B, Pavitra E, Kasa P, Peela S, Rama Raju GS, Nagaraju GP. Folate-targeted immunotherapies: Passive and active strategies for cancer. Cytokine Growth Factor Rev 2019; 45:45-52.
59. Kaur K, Khatik GL. Cancer immunotherapy: An effective tool in cancer control and treatment. Curr Cancer Ther Rev 2020; 16:62-69.
60. Schutz F, Marme F, Domschke C, Sohn C, von Au A. Immunooncology in breast cancer: active and passive vaccination strategies. Breast Care (Basel) 2018; 13:22-26.
61. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm 2011; 26:407-415.
62. Rezaei T, Davoudian E, Khalili S, Amini M, Hejazi M, de la Guardia M, et al. Strategies in DNA vaccine for melanoma cancer. Pigment Cell Melanoma Res 2021; 34:869-891.
63. Ding Y, Li Z, Jaklenec A, Hu Q. Vaccine delivery systems toward lymph nodes. Adv Drug Deliv Rev 2021; 179:113914.
64. Roy S, Sethi TK, Taylor D, Kim YJ, Johnson DB. Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside. J Leukoc Biol 2020; 108:1455-1489.
65. Truong C-S, Yoo SY. Oncolytic vaccinia virus in lung cancer vaccines. Vaccines 2022; 10:240-255.
66. Heidary F, Tourani M, Hejazi-Amiri F, Khatami SH, Jamali N, Taheri-Anganeh M. Design of a new multi-epitope peptide vaccine for non-small cell Lung cancer via vaccinology methods: An in silico study. Mol Biol Res Commun 2022; 11:55-66.
67. Zhong R, Ling X, Cao S, Xu J, Zhang B, Zhang X, et al. Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. ESMO Open 2022; 7:100334.
68. Huang T, Peng L, Han Y, Wang D, He X, Wang J, et al. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol 2022; 13:922301.
69. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer 2018; 6:75-89.
70. Oliveres H, Caglevic C, Passiglia F, Taverna S, Smits E, Rolfo C. Vaccine and immune cell therapy in non-small cell lung cancer. J Thorac Dis 2018; 10:S1602-S1614.
71. Corrales L, Scilla K, Caglevic C, Miller K, Oliveira J, Rolfo C. Immunotherapy in lung cancer: A new age in cancer treatment. Adv Exp Med Biol 2018; 995:65-95.
72. Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, et al. Immune checkpoint inhibitors for lung cancer treatment: A review. J Clin Med 2020; 9:1362-1377.
73. Van Coillie S, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol 2020;1248:7-32. 
74. Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers 2021; 13:1440-1457.
75. Zhang A, Ren Z, Tseng K-F, Liu X, Li H, Lu C, et al. Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors. Sci Transl Med 2021; 13:eabg8693.
76. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res 2019; 38:255-266.
77. Santini FC, Hellmann MD. PD-1/PD-L1 axis in lung cancer. Cancer J 2018; 24:15-19.
78. Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, et al. Immunotherapy in non-small cell lung cancer: Facts and hopes. Clin Cancer Res 2019; 25:4592-4602.
79. Zheng M, Huang J, Tong A, Yang H. Oncolytic viruses for cancer therapy: Barriers and recent advances. Mol Ther Oncolytics 2019; 15:234-247.
80. Zendedel E, Atkin SL, Sahebkar A. Use of stem cells as carriers of oncolytic viruses for cancer treatment. J Cell Physiol 2019; 2019; 234:14906-14913.
81. Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: A new class of immunotherapy drugs. Nat Rev Drug Discov 2015; 14:642-662.
82. Hemminki O, Dos Santos JM, Hemminki A. Oncolytic viruses for cancer immunotherapy. J Hematol Oncol 2020; 13:84-98.
83. Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral t cell infiltration and improves anti-pd-1 immunotherapy. Cell 2017; 170:1109-1119 e1110.
84. Ghasemi Darestani N, Gilmanova AI, Al-Gazally ME, Zekiy AO, Ansari MJ, Zabibah RS, et al. Mesenchymal stem cell-released oncolytic virus: an innovative strategy for cancer treatment. Cell Commu Signal2023; 21:1-20.
85. Mazza V, Cappuzzo F. Immunotherapy and lung cancer: From therapeutic cancer vaccination to novel approaches. J Thorac Dis 2016; 8:E1348-E1350.
86. Escribese MM, Barber D. New insight into cancer immunotherapy. Allergol Immunopathol (Madr) 2017; 45 Suppl 1:50-55.
87. Yuzhakova DV, Shirmanova MV, Sergeeva TF, Zagaynova EV, Lukyanov KA. Immunotherapy of cancer (Review). Sovrem 2016; 8:173-182.
88. Parakh S, King D, Gan HK, Scott AM. Current development of monoclonal antibodies in cancer therapy. Recent Results Cancer Res 2020;214:1-70.
89. Carter BW. Immunotherapy in lung cancer and the role of imaging. Semin Ultrasound CT MR 2018; 39:314-321.
90. Dong J, Li B, Zhou Q, Huang D. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. J Evid Based Med 2018; 11:278-287.
91. Kakimi K, Matsushita H, Murakawa T, Nakajima J. Gammadelta T cell therapy for the treatment of non-small cell lung cancer. Transl Lung Cancer Res 2014; 3:23-33.
92. Carter BW, Halpenny DF, Ginsberg MS, Papadimitrakopoulou VA, de Groot PM. Immunotherapy in non-small cell lung cancer treatment: current status and the role of imaging. J Thorac Imaging 2017; 32:300-312.
93. Rusch T, Bayry J, Werner J, Shevchenko I, Bazhin AV. Immunotherapy as an option for cancer treatment. Arch Immunol Ther Exp (Warsz) 2018; 66:89-96.
94. McFarland DC. New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects as compared to chemotherapy. Gen Hosp Psychiatry 2019; 60:148-155.
95. Pinheiro FD, Teixeira AF, de Brito BB, da Silva FAF, Santos MLC, de Melo FF. Immunotherapy - new perspective in lung cancer. World J Clin Oncol 2020; 11:250-259.
96. Aalipour S, Zoghi S, Khalili N, Hirbod-Mobarakeh A, Emens LA, Rezaei N. Specific immunotherapy in ovarian cancer: A systematic review. Immunotherapy 2016; 8:1193-1204.
97. Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol 2018; 834:188-196.
98. Alibakhshi A, Ranjbari J, Pilehvar-Soltanahmadi Y, Nasiri M, Mollazade M, Zarghami N. An update on phytochemicals in molecular target therapy of cancer: Potential inhibitory effect on telomerase activity. Curr Med Chem 2016; 23:2380-2393.
99. Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, et al. Non-small-cell lung cancer: Molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med 2013; 6:25-36.
100. Lamarca A, Barriuso J, McNamara MG, Valle JW. Molecular targeted therapies: Ready for “prime time” in biliary tract cancer. J Hepatol 2020; 73:170-185.
101. Passaro A, Jänne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer 2021; 2:377-391.
102. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B. EGFR-mutated lung cancer: A paradigm of molecular oncology. Oncotarget 2010; 1:497-514.
103. Ke X, Shen L. Molecular targeted therapy of cancer: The progress and future prospect. Front Med 2017; 1:69-75.
104. Mayekar MK, Bivona TG. Current landscape of targeted therapy in lung cancer. Clin Pharmacol Ther 2017; 102:757-764.
105. Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther 2019; 4:61-74.
106. Francis H, Solomon B. The current status of targeted therapy for non-small cell lung cancer. Intern Med J 2010; 40:611-618.
107. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 2006; 42:17-23.
108. Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 2009; 6:201-205.
109. Morgillo F, Della Corte CM, Fasano M, Ciardiello F. Mechanisms of resistance to EGFR-targeted drugs: Lung cancer. ESMO Open 2016; 1:e000060.
110. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med 2011; 3:90ra59.
111. Offin M, Rizvi H, Tenet M, Ni A, Sanchez-Vega F, Li BT, et al. Tumor mutation burden and efficacy of egfr-tyrosine kinase inhibitors in patients with egfr-mutant lung cancers. Clin Cancer Res 2019; 25:1063-1069.
112. Dong R-F, Zhu M-L, Liu M-M, Xu Y-T, Yuan L-L, Bian J, et al. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res 2021; 167:105583.
113. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, et al. Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer. Cancer Res 2019; 79:689-698.
114. Papadimitrakopoulou VA, Mok TS, Han JY, Ahn MJ, Delmonte A, Ramalingam SS, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol 2020; 31:1536-1544.
115. Mitsudomi T. Advances in target therapy for lung cancer. Jpn J Clin Oncol 2010; 40:101-106.
116. Diaz-Serrano A, Gella P, Jimenez E, Zugazagoitia J, Paz-Ares Rodriguez L. Targeting EGFR in lung cancer: Current standards and developments. Drugs 2018; 78:893-911.
117. Patel H, Pawara R, Ansari A, Surana S. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. Eur J Med Chem 2017; 142:32-47.
118. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, et al. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment. Cancer Lett 2016; 380:494-504.
119. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 Suppl 3:4-10.
120. Waldner MJ, Neurath MF. Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Pat 2012; 16:5-13.
121. Alevizakos M, Kaltsas S, Syrigos KN. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol 2013; 72:1169-1181.
122. Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors-clinical perspectives. Cell Oncol 2021; 44:715-737.
123. Frezzetti D, Gallo M, Maiello MR, D’Alessio A, Esposito C, Chicchinelli N, et al. VEGF as a potential target in lung cancer. Expert Opin Ther Targets 2017; 21:959-966.
124. Zarghami N, Grass L, Sauter ER, Diamandis EP. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 1997; 43:1862-1867.
125. Liu L, Zhang Y, Wei J, Chen Z, Yu J. VEGFR-TKIs combined with chemotherapy for advanced non-small cell lung cancer: A systematic review. J Cancer 2019; 10:799-809.
126. Wang R, Luo Z, Zhang H, Wang T. Tanshinone IIA reverses gefitinib-resistance in human non-small-cell lung cancer via regulation of VEGFR/Akt pathway. Onco Targets Ther 2019; 12:9355-9365.
127. Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, et al. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res 2017; 23:5489-5501.
128. Shaw AT, Engelman JA. ALK in lung cancer: Past, present, and future. J Clin Oncol 2013; 31:1105-1111.
129. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370:1189-1197.
130. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med 2018; 379:2027-2039.
131. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-4253.
132. Lu S, Lu C, Xiao Y, Zhu W, He Q, Xie B, et al. Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer. J Cancer 2020; 11:1525-1531.
133. Wu J, Savooji J, Liu D. Second- and third-generation ALK inhibitors for non-small cell lung cancer. J Hematol Oncol 2016; 9:19-25.
134. Tao H, Shi L, Zhou A, Li H, Gai F, Huang Z, et al. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. Lung Cancer 2020; 149:154-161.
135. Horn L, Pao W. EML4-ALK: Honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009; 27:4232-4235.
136. Elliott J, Bai Z, Hsieh SC, Kelly SE, Chen L, Skidmore B, et al. ALK inhibitors for non-small cell lung cancer: A systematic review and network meta-analysis. PLoS One 2020; 15:e0229179.
137. Tomasini P, Egea J, Souquet-Bressand M, Greillier L, Barlesi F. Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases. Ther Adv Respir Dis 2019; 13:1753466619831906.
138. Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R. Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): Patient selection and perspectives. Onco Targets Ther 2019; 12:4567-4575.
139. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71:6051-6060.
140. Ghimessy A, Radeczky P, Laszlo V, Hegedus B, Renyi-Vamos F, Fillinger J, et al. Current therapy of KRAS-mutant lung cancer. Cancer Metastasis Rev 2020; 39:1159-1177.
141. Amanam I, Mambetsariev I, Gupta R, Achuthan S, Wang Y, Pharaon R, et al. Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. J Thorac Dis 2020; 12:5086-5095.
142. Yang H, Liang SQ, Schmid RA, Peng RW. New horizons in KRAS-mutant lung cancer: Dawn after darkness. Front Oncol 2019; 9:953-965.
143. Kempf E, Rousseau B, Besse B, Paz-Ares L. KRAS oncogene in lung cancer: Focus on molecularly driven clinical trials. Eur Respir Rev 2016; 25:71-76.
144. Molina-Arcas M, Moore C, Rana S, Van Maldegem F, Mugarza E, Romero-Clavijo P, et al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci Transl Med 2019; 11:eaaw7999.
145. Rossi A. Alectinib for ALK-positive non-small-cell lung cancer. Expert Rev Clin Pharmacol 2016; 9:1005-1013.
146. Awad MM, Liu S, Rybkin, II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS(G12C) inhibition in cancer. N Engl J Med 2021; 384:2382-2393.
147. Roman M, Baraibar I, Lopez I, Nadal E, Rolfo C, Vicent S, et al. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol Cancer 2018; 17:33-46.
148. Gurtner K, Kryzmien Z, Koi L, Wang M, Benes CH, Hering S, et al. Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. Int J Cancer 2020; 147:472-477.
149. Riudavets M,  Sullivan  I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): A glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open 2021; 6:100260.
150. Ni J, Zhang L. Progress in Treatment of Non-Small Cell Lung Cancer Harboring HER2 Aberrations. Onco Targets Ther 2021; 14: 4087-4098.
151. Zhao S, Xian X, Tian P, Li W, Wang K, Li Y. Efficacy of combination chemo-immunotherapy as a first-line treatment for advanced non-small-cell lung cancer patients with HER2 alterations: A case series. Front Oncol 2021; 11:633522.
152. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer 2015; 87:220-225.
153. Bondili SK, Nandhana R, Noronha V, Pawar S, Menon N, Shetty O, et al. HER2 alterations in non-small-cell lung cancer–Druggable or undruggable? Cancer Research, Statistics, and Treatment 2021; 4:374-384.
154. Alvarez JGB, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs Context 2019; 8:212566.
155. Roviello G, D’Angelo A, Sirico M, Pittacolo M, Conter FU, Sobhani N. Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 2021; 39:879-890.
156. Yan N, Guo S, Zhang H, Zhang Z, Shen S, Li X. BRAF-mutated non-small cell lung cancer: Current treatment status and future perspective. Front Oncol 2022; 12:863043.
157. Leonetti A, Facchinetti F, Rossi G, Minari R, Conti A, Friboulet L, et al. BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. Cancer Treat Rev 2018; 66:82-94.
158. Li M, Zhang X. BRAF mutations and resistance of non-small cell lung cancer to BRAF-targeted therapies using liquid biopsy. Asia Pac J Oncol Nurs 2021; 8:110-111.
159. Araujo JM, Gomez AC, Pinto JA, Rolfo C, Raez LE. Profile of entrectinib in the treatment of ROS1-positive non-small cell lung cancer: Evidence to date. Hematol/ Oncol Stem Cell Ther 2021; 14:192-198.
160. Azelby CM, Sakamoto MR, Bowles DW. ROS1 targeted therapies: current status. Curr Oncol Rep 2021; 23:94.
161. Bubendorf L, Buttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, et al. Testing for ROS1 in non-small cell lung cancer: A review with recommendations. Virchows Arch 2016; 469:489-503.
162. Roys A, Chang X, Liu Y, Xu X, Wu Y, Zuo D. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother Pharmacol 2019; 84:679-688.
163. Choudhury NJ, Schneider JL, Patil T, Zhu VW, Goldman DA, Yang SR, et al. Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers. JTO Clin Res Rep 2021; 2:100187.
164. Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K. Does c-MET remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat Rev 2017; 61:70-81.
165. Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-MET axis. Onco Targets Ther 2020; 13:2491-2510.
166. Yu J, Zhang L, Peng J, Ward R, Hao P, Wang J, et al. Dictamnine, a novel c-MET inhibitor, suppresses the proliferation of lung cancer cells by downregulating the PI3K/AKT/mTOR and MAPK signaling pathways. Biochem Pharmacol 2022; 195:114864.
167. Oh HN, Kwak AW, Lee MH, Kim E, Yoon G, Cho SS, et al. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells. Int J Phytomedicine 2021; 80:153355.
168. Faiella A, Riccardi F, Carteni G, Chiurazzi M, Onofrio L. The emerging role of c-MET in carcinogenesis and clinical implications as a possible therapeutic target. J Oncol 2022; 2022:5179182.
169. Miranda O, Farooqui M, Siegfried JM. Status of agents targeting the HGF/c-MET axis in lung cancer. Cancers (Basel) 2018; 10:280-297.
170. Prasad RR, Mishra DK, Kumar M, Yadava PK. Human telomerase reverse transcriptase promotes the epithelial to mesenchymal transition in lung cancer cells by enhancing c-MET upregulation. Heliyon 2022; 8:e08673.
Iranian Journal of Basic Medical Sciences
Volume 27, Issue 2
February 2024
Pages 122-133

Files

Share

How to cite

Statistics